A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer
NCT01187485
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Androderm® 2.5mg
DRUG:
Androderm® 5.0mg
DRUG:
Androderm® 7.5mg
Sponsor
University of Chicago